Journal of Pharmacovigilance

Drug interactions and quality of life in patients with chronic kidney disease

3^rd International Conference and Exhibition on Pharmacovigilance & Clinical Trials

October 27-29, 2014 Hyderabad International Convention Centre, India

Kamineni Phani Syam

Posters: J Pharmacovigilance

Abstract:

Chronic kidney disease (CKD), also known as chronic renal disease (CRD), is a progressive loss in renal function over a period of months or years. The symptoms of worsening kidney function are non-specific, and might include feeling generally unwell and experiencing a reduced appetite. Often, chronic kidney disease is diagnosed as a result of screening of people known to be at risk of kidney problems, such as those with high blood pressure or diabetes and those with a blood relative with chronic kidney disease. Chronic kidney disease may also be identified when it leads to one of its recognised complications, such as cardiovascular disease, anaemia or pericarditis. It is differentiated from acute kidney disease in that the reduction in kidney function must be present for over 3 months. Our study emphasises on knowing the Quality of Life (QoL) of CKD patients and potential Drug Interactions, a total of 50 CKD patients were admitted to the study, out of which 33 patients were male (66%) and 17 patients were female (34%). The mean age of the patients was 57.64 with standard deviation 13.77 ranging from 25 to 85 years. 32% of the patients were between 50-59 years of age which was the most prevailing age group in both genders and 30% of the patients were aged 60-69, which was the second most prevailing age group, both these age group constitute of about 62% of the total study population. The highest QoL was observed in patients between ages 20-29 with an average QoL of 63.3 (SD?1.23). The age group of patients 50-59 who were the most populated group in the study averaged about 50.12 (SD?7.81). The lowest QoL was observed in patients of age group 80-89 with an average of 30.23 (SD?4.98). 58% (29 patients) of the study population were found to have a fair quality of life, 38% (19 patients) were found to have a good quality of life and 4% (2 patients) were found to be having a very good quality of life.

Biography :

Kamineni Phani Syam is currently doing his Doctor of Pharmacy (PharmD) 6th year (Internship) from PES College of Pharmacy Bangalore affiliated with Rajiv Gandhi University of Health Sciences. He is an active research scholar and an aspirant clinical researcher. His areas of interest are Pharmacovigilance, Quality of life estimation, Clinical trials, Drug related problems, Pharmacoeconomics.